OGT launches enhanced SureSeq™ Interpret NGS analysis software
Oxford, UK – 07 August 2018. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced the launch of the eagerly-anticipated update to its SureSeq™ Interpret software, included with purchases of SureSeq NGS panels. Designed to help researchers effortlessly translate cumbersome NGS data into meaningful results, OGT has leveraged its renowned bioinformatics expertise to develop the new, significantly enhanced software in response to customer needs. The company, well known for its popular and highly-regarded CytoSure™ Interpret microarray analysis software, will with SureSeq Interpret, deliver an easy-to-use, accurate and precise NGS analysis solution that offers extensive flexibility to meet individual laboratory requirements.
SureSeq Interpret has been designed to be used with SureSeq NGS panels, facilitating analysis and visualisation of a wide range of mutation types and structural variants. Working in tandem with OGT’s expert panel design and hybridisation-based approach that delivers unparalleled coverage uniformity in sequencing reactions, SureSeq Interpret is integral to enabling low-frequency variants to be detected confidently and consistently.
Powerful and easy-to-use, the software rapidly processes sequencing data and delivers accurate mutation calling with 100% sensitivity and 99.9% specificity at >1% variant allele frequency (VAF)*. SureSeq Interpret reliably identifies single nucleotide variants (SNVs) and Indels as well as structural variants such as copy number variants (CNVs) and internal tandem duplications (ITDs) - meaning that researchers can rely on the software for all their mutation detection and analysis needs. Beta triallist Joshua Landreth, Molecular Laboratory Supervisor at Genetic Associates Inc, observed “The software provided quick and reliable alignment and variant analysis to interpret results from our core MPN sequencing.”
A comprehensive filtering framework enables analysis workflows to be standardised and allows variant filtering to be overlaid to meet analytical criteria. Extensive customisation options enable researchers to easily tailor variant and batch reports and database links to meet the exact needs of the laboratory. Flexibility and ease of use is integral to the design, and features accessibility via a stand-alone computer, laboratory server or other web-enabled devices. Finally, security and control have also been well-provisioned for, with a built-in ability to log and track user activity and standardise analysis protocols via multiple access permission levels.
Dave Cook, Senior Product Manager at OGT, commented, “We are delighted to be offering these enhanced capabilities for our SureSeq Interpret software to complement our world-class custom bait design, panel development and library preparation. We realised there was a gap for freely-available, accurate and precise NGS analysis software that also offers a high degree of flexibility in terms of analysis, filtering options, and security controls and SureSeq Interpret has been developed to address that need. OGT is well known for our highly-rated CytoSure Interpret microarray analysis software, and SureSeq Interpret follows on from that. We want to enable researchers to focus on their research, rather than struggling to sift through data.”
* Sensitivity and specificity determined using Horizon Discovery OncoSpan and TruQ7 and HapMap (NA12878) standards.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856807; F: +44 (0) 1865 848684
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitro diagnostic company in June 2017. The acquisition of OGT expands Sysmex’s life science business and reinforces its initiatives towards personalised medicine.
CytoSure™ and SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures. Cytocell®: Some products may not be available in your region
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 40 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs about 8,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit http://www.sysmex.co.jp/en/.